# Discovery of antiviral inhibitors of Ebola virus replication

> **NIH NIH R43** · VENATORX PHARMACEUTICALS, INC. · 2021 · $300,000

## Abstract

Ebola viruses (EBOV) cause severe illnesses in humans with a high rate of mortality that approaches 90%.
Novel therapies with potent and selective activity against EBOV are urgently needed for the prevention and
treatment of Ebola virus disease (EVD). We propose to execute an innovative high throughput screening
campaign using a unique reverse genetics system. This screen is expected to yield new inhibitors targeting
EBOV replication that will serve as starting points for medicinal chemistry hit-to-lead efforts. If successful, we
will deliver one or more new lead series targeting EBOV infection.

## Key facts

- **NIH application ID:** 10216627
- **Project number:** 5R43AI152672-02
- **Recipient organization:** VENATORX PHARMACEUTICALS, INC.
- **Principal Investigator:** Glen Coburn
- **Activity code:** R43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $300,000
- **Award type:** 5
- **Project period:** 2020-07-15 → 2022-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10216627

## Citation

> US National Institutes of Health, RePORTER application 10216627, Discovery of antiviral inhibitors of Ebola virus replication (5R43AI152672-02). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10216627. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*